anest-shutterstock

Anest / Shutterstock.com

2 July 2020BiotechnologyAnna Gregson

EPO’s G3/19: no turning back?

In its decision G3/19, issued in May, the European Patent Office’s (EPO) Enlarged Board of Appeal (EBA) held that plants, plant material, and animals exclusively obtained by an essentially biological process are not patentable.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UPC bans Meril Life Sciences from selling infringing heart valve

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sanofi subsidiary fends off $450m trade secrets case